Education
About Us
Working with TipRanks
Follow Us
Lepu Biopharma Co. Ltd. Class H (HK:2157)
:2157
RESEARCH TOOLSreports
2157 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.16 - HK$6.44
Previous CloseN/A
Volume4.02M
Average Volume (3M)20.07M
Market Cap
HK$9.10B
Enterprise ValueHK$10.67B
Total Cash (Recent Filing)HK$464.91M
Total Debt (Recent Filing)¥850.16M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding1,656,346,400
10 Day Avg. Volume32,841,579
30 Day Avg. Volume20,070,842
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)11.82
Price to Sales (P/S)0.00
P/FCF Ratio-18.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Lepu Biopharma Co. Ltd. Class H News
PremiumCompany Announcements
Lepu Biopharma Secures Hong Kong Stock Exchange Listing Approval
PremiumCompany Announcements
Lepu Biopharma Announces 2024 AGM with Key Resolutions
PremiumCompany Announcements
Lepu Biopharma Announces Board Changes with New Director Appointment
PremiumCompany Announcements
Lepu Biopharma Advances H Share Circulation with CSRC FilingPremiumCompany Announcements
Lepu Biopharma’s MRG003 Gains Recognition at 2025 ASCO Annual Meeting
PremiumCompany Announcements
Lepu Biopharma Schedules Board Meeting to Review Annual ResultsOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
― Other Institutional Investors
99.26% Public Companies and
Individual Investors
2157 FAQ
What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$2.16 and its highest was HK$6.44 in the past 12 months.
What is Lepu Biopharma Co. Ltd. Class H’s market cap?
Lepu Biopharma Co. Ltd. Class H’s market cap is HK$9.10B.
When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date is Aug 21, 2025 which is in 60 days.
How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
Lepu Biopharma Co. Ltd. Class H released its earnings results on Mar 27, 2025. The company reported -HK$0.139 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.139.
Is Lepu Biopharma Co. Ltd. Class H overvalued?
According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Overvalued.
Does Lepu Biopharma Co. Ltd. Class H pay dividends?
Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
Lepu Biopharma Co. Ltd. Class H has 1,656,346,400 shares outstanding.
What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
Lepu Biopharma Co. Ltd. Class H reported an EPS of -HK$0.139 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.153%.
Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2157
Lepu Biopharma Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.05%
12-Months-Change
Fundamentals
Return on Equity
-51.40%
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Company Description
Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.
Technical Analysis
CSPC Pharmaceutical Group
―
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―